Inovio Pharmaceuticals, INC. (INO) — SEC Filings

Q: What are the key financial highlights for Inovio Pharmaceuticals, INC.?

Key financial highlights for Inovio Pharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Inovio Pharmaceuticals, INC.?

Key executives at Inovio Pharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Inovio Pharmaceuticals, INC. stock?

Risk factors for Inovio Pharmaceuticals, INC. (INO) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Inovio Pharmaceuticals, INC.?

Forward-looking statements and predictions from Inovio Pharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Inovio Pharmaceuticals, INC.. Recent 8-K filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Inovio Pharmaceuticals, INC. on SEC EDGAR

Overview

Inovio Pharmaceuticals, INC. (INO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 6, 2026: On April 2, 2026, INOVIO PHARMACEUTICALS, INC. entered into a material definitive agreement. The filing also includes other events and financial statements/exhibits related to this report.

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 2 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Inovio Pharmaceuticals, INC. is neutral.

Filing Type Overview

Inovio Pharmaceuticals, INC. (INO) has filed 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

INOVIO PHARMACEUTICALS, INC. Files 8-K — 8-K · Apr 6, 2026 Risk: medium
On April 2, 2026, INOVIO PHARMACEUTICALS, INC. entered into a material definitive agreement. The filing also includes other events and financial statements/exhi
8-K Filing — 8-K · Apr 2, 2026
8-K Filing — 8-K · Dec 29, 2025
Inovio Pharmaceuticals Files 8-K with Material Agreement — 8-K · Nov 12, 2025 Risk: medium
On November 11, 2025, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and fina
Inovio's Losses Widen Amidst Going Concern Doubts — 10-Q · Nov 10, 2025 Risk: high
INOVIO PHARMACEUTICALS, INC. reported a significant increase in net loss for the three and nine months ended September 30, 2025, reaching $45.5 million and $88.
INOVIO Narrows Q2 Loss to $30.5M Amid Pipeline Progress — 10-Q · Aug 12, 2025 Risk: high
INOVIO PHARMACEUTICALS, INC. reported a net loss of $30.5 million for the second quarter of 2025, a significant improvement from the $45.2 million net loss in t
Inovio Pharmaceuticals Files 8-K — 8-K · Jul 7, 2025 Risk: medium
On July 2, 2025, Inovio Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statem
Inovio Pharmaceuticals Files 8-K on Security Holder Vote — 8-K · May 22, 2025 Risk: low
On May 20, 2025, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not specify t
INOVIO Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
INOVIO Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
INOVIO Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · Apr 7, 2025 Risk: medium
INOVIO Pharmaceuticals, Inc. filed its DEF 14A on April 7, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and boa
Inovio Pharmaceuticals Files 2024 10-K — 10-K · Mar 18, 2025 Risk: medium
Inovio Pharmaceuticals, Inc. filed its 2024 10-K on March 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware
Inovio Pharmaceuticals Files 8-K — 8-K · Dec 16, 2024 Risk: medium
On December 12, 2024, Inovio Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stat
INOVIO Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
INOVIO Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operational update
SC 13G Filing — SC 13G · Nov 8, 2024
SC 13G Filing — SC 13G · Oct 22, 2024
Inovio Pharmaceuticals Files Material Definitive Agreement — 8-K · Aug 13, 2024 Risk: medium
On August 13, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing does not provide specific details on
Inovio Pharmaceuticals Files 8-K with Financial Updates — 8-K · Aug 8, 2024 Risk: medium
On August 8, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and
INOVIO Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
INOVIO Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported a net loss for the three and six months ended June 30, 202
Inovio Pharmaceuticals Elects Directors, Ratifies Auditors — 8-K · May 28, 2024 Risk: low
On May 21, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a shareholder meeting held on May 20, 2024. The meeting included the election of two
Inovio Pharmaceuticals Files 8-K with Financial Updates — 8-K · May 13, 2024 Risk: medium
On May 13, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and e
Inovio Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
INOVIO PHARMACEUTICALS, INC. (INO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Inovio Pharmaceuticals, Inc. filed a 10-Q report for the period
SC 13G Filing — SC 13G · Apr 26, 2024
Inovio Pharmaceuticals Files 8-K: Material Agreement — 8-K · Apr 17, 2024 Risk: medium
On April 15, 2024, Inovio Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on other events and filed financial stat
Inovio Pharmaceuticals Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 11, 2024 Risk: low
INOVIO PHARMACEUTICALS, INC. (INO) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Inovio Pharmaceuticals, Inc. will hold its virtual Annual M
INOVIO PHARMACEUTICALS, INC. Files 2023 Annual Report on Form 10-K — 10-K · Mar 6, 2024 Risk: medium
INOVIO PHARMACEUTICALS, INC. (INO) filed a Annual Report (10-K) with the SEC on March 6, 2024. INOVIO PHARMACEUTICALS, INC. filed its 2023 Form 10-K on March 6,
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Inovio Files 8-K on Bylaw Amendments; Governance Changes Ahead — 8-K · Jan 25, 2024
Inovio Pharmaceuticals, Inc. filed an 8-K on January 25, 2024, reporting an event from January 24, 2024, related to amendments to its Articles of Incorporation
State Street Exits INOVIO PHARMACEUTICALS Stake — SC 13G/A · Jan 22, 2024
State Street Corp, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of INOVIO PHARMACEUTICALS, INC. common
Inovio Files 8-K on Shareholder Vote Submission — 8-K · Jan 12, 2024
Inovio Pharmaceuticals, Inc. filed an 8-K on January 12, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the

Risk Profile

Risk Assessment: Of INO's 20 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Inovio Pharmaceuticals, INC.'s most recent 10-Q filing (Nov 10, 2025):

Revenue: $65,343
Net Income: $-88.7M
EPS: $-2.12
Debt-to-Equity: N/A
Cash Position: $36.6M
Operating Margin: N/A
Total Assets: $69.4M
Total Debt: $77.1M

Key Executives

Jacqueline E. Shea, Ph.D.
J. Joseph Kim, Ph.D.
Dr. Niranjan Bose
Ms. Joanne Lord

Industry Context

The biotechnology sector, particularly companies focused on vaccine development, is highly competitive and capital-intensive. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies. Companies often rely on partnerships and significant R&D investment, facing challenges in revenue generation until products reach the market.

Top Tags

material-agreement (6) · filing (6) · corporate-governance (5) · Biotechnology (4) · 10-Q (4) · pharmaceuticals (3) · financials (3) · Net Loss (2) · 10-K (2) · financial-results (2)

Key Numbers

Net Loss (Q3 2025): $45.5M — Increased from $25.2M in Q3 2024
Net Loss (YTD Q3 2025): $88.7M — Increased from $87.9M in YTD Q3 2024
Change in fair value of common stock warrant liabilities: $20.7M — Major contributor to increased net loss in YTD Q3 2025
Cash and cash equivalents (Sept 30, 2025): $36.6M — Decreased from $65.8M at Dec 31, 2024
Working Capital (Sept 30, 2025): $(14.6)M — Indicates a significant deficit and going concern risk
Research and development expenses (YTD Q3 2025): $43.9M — Decreased by 30% from $62.7M in YTD Q3 2024
General and administrative expenses (YTD Q3 2025): $25.5M — Decreased from $29.4M in YTD Q3 2024
Accumulated Deficit (Sept 30, 2025): $1.8B — Reflects sustained historical losses
Common Shares Outstanding (Nov 7, 2025): 53,571,675 — Increased from 36,099,991 at Dec 31, 2024, indicating dilution
Net loss per share (Q3 2025): $0.87 — Compared to $0.89 in Q3 2024, despite higher net loss due to increased share count
Net Loss: $30.5M — Q2 2025 net loss, an improvement from $45.2M in Q2 2024
Reporting Period: 2025 Q1 — First quarter of 2025 financial reporting
As of Date: 2025-03-31 — End of the reporting period
Prior Period End: 2024-12-31 — End of the previous fiscal year
Fiscal Year: 2024 — Compensation details for this year are included.

Frequently Asked Questions

What are the latest SEC filings for Inovio Pharmaceuticals, INC. (INO)?

Inovio Pharmaceuticals, INC. has 29 recent SEC filings from Jan 2024 to Apr 2026, including 14 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of INO filings?

Across 29 filings, the sentiment breakdown is: 2 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Inovio Pharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Inovio Pharmaceuticals, INC. (INO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Inovio Pharmaceuticals, INC.?

Key financial highlights from Inovio Pharmaceuticals, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for INO?

The investment thesis for INO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Inovio Pharmaceuticals, INC.?

Key executives identified across Inovio Pharmaceuticals, INC.'s filings include Jacqueline E. Shea, Ph.D., J. Joseph Kim, Ph.D., Dr. Niranjan Bose, Ms. Joanne Lord.

What are the main risk factors for Inovio Pharmaceuticals, INC. stock?

Of INO's 20 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 3 low-risk.

What are recent predictions and forward guidance from Inovio Pharmaceuticals, INC.?

Forward guidance and predictions for Inovio Pharmaceuticals, INC. are extracted from SEC filings as they are enriched.